Yu Fujiwara

Yu Fujiwara

Roswell Park Comprehensive Cancer Center - Buffalo / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 5723591
Roswell Park Cancer Institute
person_outline Yu Fujiwara's MOST POPULAR ARTICLES
1-) Indoleamine 2, 3-dioxygenase (IDO) inhibitors and cancer immunotherapy Cancer treatment reviews 110, 102461, 2022
2-) A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy Cancer Drug Resistance 2020 (3), 2020
3-) Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review … The Lancet Oncology 25 (1), 62-75, 2024
4-) Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib In Vivo 34 (5), 2859-2864, 2020
5-) Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-Mutant NSCLC: a multicenter retrospective cohort study Journal of Thoracic Oncology 19 (6), 928-940, 2024